Creation of a nonspreading rift valley fever virus

Journal of Virology

Volumn 85, Issue 23, 2011, Pages 12622-12630

  Kortekaas, Jeroen ^a   Oreshkova, Nadia ^a   Cobos Jiménez, Viviana ^a,c   Vloet, Rianka P M ^a   Potgieter, Christiaan A ^b,d   Moormann, Rob J M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b ONDERSTEPOORT VETERINARY INSTITUTE   (South Africa)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Deltamune (Pty) Ltd   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLYCINE; GREEN FLUORESCENT PROTEIN; RIFT VALLEY FEVER VIRUS REPLICON PARTICLE VACCINE; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSAFETY; CELL LINE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REPEATED DRUG DOSE; REPLICON; RIFT VALLEY FEVER BUNYAVIRUS; SINGLE DRUG DOSE; SURVIVAL RATE; VACCINATION; VACCINE PRODUCTION; VIRUS GENE; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ANIMALS; BLOTTING, NORTHERN; CRICETINAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ENGINEERING; GENOME, VIRAL; GREEN FLUORESCENT PROTEINS; INJECTIONS, INTRAMUSCULAR; KIDNEY; MICE; MICE, INBRED BALB C; PLASMIDS; RECOMBINATION, GENETIC; REPLICON; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SURVIVAL RATE; VACCINATION; VIRAL NONSTRUCTURAL PROTEINS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HEXAPODA; MAMMALIA; MUS; ORTHOBUNYAVIRUS; PHLEBOVIRUS; RIFT VALLEY FEVER VIRUS;

EID: 81255179998     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00841-11     Document Type: Article

References (47)

1. Adam, A. A., M. S. Karsany, and I. Adam. 2010. Manifestations of severe Rift Valley fever in Sudan. Int. J. Infect. Dis. 14:e179-180.
2. Al-Hazmi, M., et al. 2003. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin. Infect. Dis. 36:245-252.
3. Barnard, B. J. 1979. Rift Valley fever vaccine-antibody and immune response in cattle to a live and an inactivated vaccine. J. S. Afr. Vet. Assoc. 50:155-157.
4. Bergeron, E., M. J. Vincent, and S. T. Nichol. 2007. Crimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivity. J. Virol. 81:13271-13276.
5. Billecocq, A., et al. 2004. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J. Virol. 78: 9798-9806.
6. Billecocq, A., P. Vialat, and M. Bouloy. 1996. Persistent infection of mammalian cells by Rift Valley fever virus. J. Gen. Virol. 77:3053-3062.
7. Bird, B. H., C. G. Albarino, and S. T. Nichol. 2007. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362:10-15.
8. Bird, B. H., M. L. Khristova, P. E. Rollin, T. G. Ksiazek, and S. T. Nichol. 2007. Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. J. Virol. 81:2805-2816.
9. Bird, B. H., T. G. Ksiazek, S. T. Nichol, and N. J. MacLachlan. 2009. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234:883-893.
10. Boshra, H., G. Lorenzo, N. Busquets, and A. Brun. 2011. Rift valley Fever: recent insights into pathogenesis and prevention. J. Virol. 85:6098-6105.
11. Boshra, H., G. Lorenzo, F. Rodriguez, and A. Brun. 2011. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR-/- mice upon lethal virus challenge. Vaccine 29:4469-4475.
12. Bouloy, M., and R. Flick. 2009. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res. 84:101-118.
13. Bouloy, M., et al. 2001. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J. Virol. 75:1371-1377.
14. Bridgen, A., and R. M. Elliott. 1996. Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs. Proc. Natl. Acad. Sci. U. S. A. 93:15400-15404.
15. Britton, P., et al. 1996. Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus. J. Gen. Virol. 77:963-967.
16. Coetzer, J. A. 1977. The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J. Vet. Res. 44:205-211.
17. Coetzer, J. A. 1982. The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses. Onderstepoort J. Vet. Res. 49:11-17.
18. Das, S. C., M. D. Baron, M. A. Skinner, and T. Barrett. 2000. Improved technique for transient expression and negative strand virus rescue using fowlpox T7 recombinant virus in mammalian cells. J. Virol. Methods 89:119-127.
19. Davies, F. G. 2010. The historical and recent impact of Rift Valley fever in Africa. Am. J. Trop. Med. Hyg. 83:73-74.
20. de Boer, S. M., et al. 2010. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28:2330-2339.
21. Elliott, R. M. 1996. The Bunyaviridae. Plenum Press, New York, NY.
22. Gerdes, G. H. 2004. Rift Valley fever. Rev. Sci. Tech. 23:613-623.
23. Habjan, M., N. Penski, M. Spiegel, and F. Weber. 2008. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J. Gen. Virol. 89:2157-2166.
24. Habjan, M., et al. 2009. Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology 385:400-408.
25. Ikegami, T., et al. 2009. Rift Valley fever virus NSs protein promotes posttranscriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog. 5:e1000287.
26. Ikegami, T., S. Won, C. J. Peters, and S. Makino. 2006. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J. Virol. 80:2933-2940.
27. Karber, G. 1931. Betrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Path. Pharmak. 162:480-483.
28. Kortekaas, J., et al. 2010. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 28:4394-4401.
29. Liu, L., C. C. Celma, and P. Roy. 2008. Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol. J. 5:82.
30. Lowen, A. C., C. Noonan, A. McLees, and R. M. Elliott. 2004. Efficient bunyavirus rescue from cloned cDNA. Virology 330:493-500.
31. Mandell, R. B., et al. 2010. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397:187-198.
32. Mandell, R. B., et al. 2010. Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles. J. Virol. Methods 169:259-268.
33. Moutailler, S., G. Krida, F. Schaffner, M. Vazeille, and A. B. Failloux. 2008. Potential vectors of Rift Valley fever virus in the Mediterranean region. Vector Borne Zoonotic Dis. 8:749-753.
34. Muller, R., et al. 1995. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 53:405-411.
35. Naslund, J., et al. 2009. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 385:409-415.
36. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.
37. OIE. 2008. Manual of diagnostic tests and vaccines for terrestrial animals, 6th ed., Chapter 2.1.14, p. 323-333. OIE, Paris, France. http://www.oie.int/en/international-standard-setting/terrestrial-manual/access-online/.
38. Pepin, M., M. Bouloy, B. H. Bird, A. Kemp, and J. Paweska. 2010. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 41:61.
39. Pichlmair, A., M. Habjan, H. Unger, and F. Weber. 2010. Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus. Vector Borne Zoonotic Dis. 10:701-703.
40. Piper, M. E., D. R. Sorenson, and S. R. Gerrard. 2011. Efficient cellular release of Rift Valley fever virus requires genomic RNA. PLoS One 6:e18070.
41. Potgieter, A. C., et al. 2009. Improved strategies for sequence-independent amplification and sequencing of viral double-stranded RNA genomes. J. Gen. Virol. 90:1423-1432.
42. Spearman, C. 1908. The method of right and wrong cases (constant stimuli) without Gauss's formulae. Br. J. Psychol. 2:227-242.
43. Terasaki, K., S. Murakami, K. G. Lokugamage, and S. Makino. 2010. Mechanism of tripartite RNA genome packaging in Rift Valley fever virus. Proc. Natl. Acad. Sci. U. S. A. 108:804-809.
44. Turell, M. J., et al. 2008. Potential for North American mosquitoes to transmit Rift Valley fever virus. J. Am. Mosq. Control. Assoc. 24:502-507.
45. Turell, M. J., W. C. Wilson, and K. E. Bennett. 2010. Potential for North American mosquitoes (Diptera: Culicidae) to transmit Rift Valley fever virus. J. Med. Entomol. 47:884-889.
46. Won, S., T. Ikegami, C. J. Peters, and S. Makino. 2007. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81:13335-13345.
47. Yu, X. J., et al. 2011. Fever with thrombocytopenia associated with a novel bunyavirus in China. N. Engl. J. Med. 364:1523-1532.